Predictors and ocular outcomes of rescue treatment in preterm infants with treated retinopathy of prematurity—a retrospective study

[1]  N. Marlow,et al.  Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial , 2019, The Lancet.

[2]  C. Gilbert,et al.  Retinopathy of prematurity - A world update. , 2019, Seminars in perinatology.

[3]  G. Natarajan,et al.  Neurodevelopmental Outcomes of Preterm Infants With Retinopathy of Prematurity by Treatment , 2019, Pediatrics.

[4]  A. Razak,et al.  Association of small for gestational age with retinopathy of prematurity: a systematic review and meta-analysis , 2019, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[5]  S. Honavar.  Do we need India-specific retinopathy of prematurity screening guidelines? , 2019, Indian journal of ophthalmology.

[6]  D. Moshfeghi,et al.  A Spectrum of Regression Following Intravitreal Bevacizumab in Retinopathy of Prematurity. , 2019, American journal of ophthalmology.

[7]  G. Abbott.  Detachment , 2018, Thucydides.

[8]  A. Mathur,et al.  Early Red Cell Transfusion is Associated with Development of Severe Retinopathy of Prematurity , 2018, Journal of Perinatology.

[9]  Parijat Chandra,et al.  Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. , 2018, The Cochrane database of systematic reviews.

[10]  Steven P. Miller,et al.  Severe retinopathy of prematurity predicts delayed white matter maturation and poorer neurodevelopment , 2017, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[11]  Guoming Zhang,et al.  COMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY , 2017, Retina.

[12]  L. Lehtonen,et al.  International variations and trends in the treatment for retinopathy of prematurity , 2017, British Journal of Ophthalmology.

[13]  C. Bunce,et al.  Treatment trends for retinopathy of prematurity in the UK: active surveillance study of infants at risk , 2017, BMJ Open.

[14]  K. Falavarjani,et al.  Refractive outcomes following the treatment of retinopathy of prematurity in the anti-VEGF era: a literature review. , 2016, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

[15]  A. Hellström,et al.  Ophthalmologic Outcome of Extremely Preterm Infants at 6.5 Years of Age: Extremely Preterm Infants in Sweden Study (EXPRESS). , 2016, JAMA ophthalmology.

[16]  F. Lefebvre,et al.  Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity , 2016, Pediatrics.

[17]  Rachelle G. Anzures,et al.  Practice Patterns in Retinopathy of Prematurity Treatment for Disease Milder Than Recommended by Guidelines. , 2016, American journal of ophthalmology.

[18]  V. Bhat,et al.  Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. , 2016, The Cochrane database of systematic reviews.

[19]  Wei-Chi Wu,et al.  Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment , 2016, PloS one.

[20]  A. Hutchinson,et al.  Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis. , 2015, Ophthalmology.

[21]  A. Chuang,et al.  Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. , 2014, JAMA ophthalmology.

[22]  Y. Hwang,et al.  Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes , 2014, Eye.

[23]  C. Bunce,et al.  Relationships between maternal ethnicity, gestational age, birth weight, weight gain, and severe retinopathy of prematurity. , 2013, The Journal of pediatrics.

[24]  Alice Z Chuang,et al.  Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. , 2011, The New England journal of medicine.

[25]  R. Hardy,et al.  Astigmatism in the Early Treatment for Retinopathy Of Prematurity Study: findings to 3 years of age. , 2009, Ophthalmology.

[26]  R. Hardy,et al.  Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings to 3 years of age. , 2008, Ophthalmology.

[27]  G. Holmström,et al.  Long-term follow-up of visual functions in prematurely born children--a prospective population-based study up to 10 years of age. , 2008, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

[28]  M. Trese,et al.  Evolution of retinal detachment in posterior retinopathy of prematurity: impact on treatment approach. , 2008, American journal of ophthalmology.

[29]  S. Schwartz,et al.  ASSOCIATION OF SYSTEMIC RISK FACTORS WITH THE PROGRESSION OF LASER-TREATED RETINOPATHY OF PREMATURITY TO RETINAL DETACHMENT , 2008, Retina.

[30]  Anna L. Ells,et al.  The International Classification of Retinopathy of Prematurity revisited. , 2005, Archives of ophthalmology.

[31]  W. Tasman,et al.  Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. , 2004, Archives of ophthalmology.

[32]  A. Fielder,et al.  Preliminary results of treatment of eyes with high-risk prethreshold retinopathy of prematurity in the early treatment for retinopathy of prematurity randomized trial. , 2003, Archives of ophthalmology.

[33]  C. Gilbert,et al.  Childhood blindness in the context of VISION 2020--the right to sight. , 2001, Bulletin of the World Health Organization.

[34]  J. M. Miller,et al.  Spectacle prescribing recommendations of AAPOS members. , 1998, Journal of pediatric ophthalmology and strabismus.

[35]  G. Quinn,et al.  Myopia of prematurity: nature, nurture, or disease? , 1997, The British journal of ophthalmology.